WAVE LIFE SCIENCES LTD. Increase (Decrease) in Prepaid Expense
WAVE LIFE SCIENCES LTD. (WVE) reported Increase (Decrease) in Prepaid Expense of $3.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was -$1.10M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was $4.83M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was $1.74M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was -$47.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for fiscal 2025 was -$1.15M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for fiscal 2024 was -$368.00K, a 118.59% decline from fiscal 2023.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for fiscal 2023 was $1.98M, a 46.88% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. increase (decrease) in prepaid expense for fiscal 2022 was $1.35M.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.73M 10-Q · filed 2026-07-30 | $5.47M derived: sum of 3 quarters · filed 2026-07-30 | $5.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $4.83M 10-Q · filed 2026-04-28 | $6.57M derived: sum of 2 quarters · filed 2026-04-28 | $6.53M derived: sum of 3 quarters · filed 2026-04-28 | $5.16M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.70M derived: sum of 2 quarters · filed 2026-02-26 | $333.00K derived: sum of 3 quarters · filed 2026-07-30 | -$1.15M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.41M derived: sum of 2 quarters · filed 2026-07-30 | -$2.89M 10-Q · filed 2025-11-10 | -$3.92M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.84M 10-Q · filed 2026-07-30 | -$3.87M derived: sum of 3 quarters · filed 2026-07-30 | -$5.45M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$1.48M 10-Q · filed 2026-04-28 | -$2.51M derived: sum of 2 quarters · filed 2026-04-28 | -$4.08M derived: sum of 3 quarters · filed 2026-04-28 | -$3.08M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.60M derived: sum of 2 quarters · filed 2026-02-26 | -$1.59M derived: sum of 3 quarters · filed 2026-02-26 | -$368.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$567.00K derived: sum of 2 quarters · filed 2025-11-10 | $660.00K 10-Q · filed 2025-11-10 | $3.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $2.23M 10-Q · filed 2025-07-30 | $4.63M derived: sum of 3 quarters · filed 2026-02-26 | $3.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.23M 10-Q · filed 2025-05-08 | $3.63M derived: sum of 2 quarters · filed 2026-02-26 | $2.13M derived: sum of 3 quarters · filed 2026-02-26 | $1.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $900.00K derived: sum of 2 quarters · filed 2026-02-26 | $681.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.98M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.72M derived: sum of 2 quarters · filed 2024-11-12 | -$418.00K 10-Q · filed 2024-11-12 | $95.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | -$219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.08M 10-Q · filed 2024-08-08 | $1.59M derived: sum of 3 quarters · filed 2025-03-04 | $3.62M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-10 | $1.81M derived: sum of 2 quarters · filed 2025-03-04 | $3.83M derived: sum of 3 quarters · filed 2025-03-04 | $2.29M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $2.54M derived: sum of 2 quarters · filed 2025-03-04 | $992.00K derived: sum of 3 quarters · filed 2025-03-04 | $1.35M 10-K · filed 2025-03-04 |
| 2022-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $479.00K derived: sum of 2 quarters · filed 2023-11-09 | $835.00K 10-Q · filed 2023-11-09 | -$208.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.19M 10-Q · filed 2023-08-03 | -$2.23M derived: sum of 3 quarters · filed 2023-08-03 | -$3.79M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $356.00K 10-Q · filed 2023-05-03 | -$687.00K derived: sum of 2 quarters · filed 2023-05-03 | -$2.25M derived: sum of 3 quarters · filed 2023-05-03 | -$3.49M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$2.60M derived: sum of 2 quarters · filed 2023-03-23 | -$3.85M derived: sum of 3 quarters · filed 2023-03-23 | -$3.85M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$2.80M derived: sum of 2 quarters · filed 2022-11-10 | -$2.81M 10-Q · filed 2022-11-10 | -$339.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.25M 10-Q · filed 2022-08-11 | $1.22M derived: sum of 3 quarters · filed 2022-08-11 | $2.74M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$4.00K 10-Q · filed 2022-05-12 | $2.46M derived: sum of 2 quarters · filed 2022-05-12 | $3.98M derived: sum of 3 quarters · filed 2022-05-12 | $431.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.98M derived: sum of 2 quarters · filed 2022-03-03 | $435.00K derived: sum of 3 quarters · filed 2022-03-03 | $808.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$2.03M derived: sum of 2 quarters · filed 2021-11-10 | -$1.66M 10-Q · filed 2021-11-10 | $6.15M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$3.17M 10-Q · filed 2021-08-05 | $4.64M derived: sum of 3 quarters · filed 2021-08-05 | -$824.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $373.00K 10-Q · filed 2021-05-13 | $8.19M derived: sum of 2 quarters · filed 2021-05-13 | $2.72M derived: sum of 3 quarters · filed 2021-05-13 | $2.95M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $2.35M derived: sum of 2 quarters · filed 2021-03-04 | $2.58M derived: sum of 3 quarters · filed 2021-03-04 | $3.67M 10-K · filed 2021-03-04 |
| 2019-09-30 | -$5.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$5.24M derived: sum of 2 quarters · filed 2020-11-09 | -$4.15M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.31M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $1.09M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $1.83M 10-K · filed 2020-03-02 | |||
| 2017-12-31 | $3.43M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |